Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Authors
Chang VC, Khan AA, Huang WY, Katki HA, Purdue MP, Landgren O, Hofmann JN
Affiliations
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. chidan.chang@nih.gov.
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
- Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Abstract
N/APublication Details
PubMed ID
35365600
Digital Object Identifier
10.1038/s41408-022-00642-4
Publication
Blood Cancer J. 2022 Apr 1; Volume 12 (Issue 4): Pages 51
- PLCO-355: Evaluating circulating immunologic markers in the development of multiple myeloma (Jonathan Hofmann - 2018 )